Moody Aldrich Partners LLC Acquires Shares of 58,688 Viridian Therapeutics, Inc. (NASDAQ:VRDN)

Moody Aldrich Partners LLC acquired a new stake in Viridian Therapeutics, Inc. (NASDAQ:VRDN - Free Report) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund acquired 58,688 shares of the company's stock, valued at approximately $1,125,000. Moody Aldrich Partners LLC owned 0.07% of Viridian Therapeutics as of its most recent SEC filing.

Other hedge funds have also bought and sold shares of the company. FMR LLC raised its holdings in shares of Viridian Therapeutics by 16.8% during the third quarter. FMR LLC now owns 11,183,478 shares of the company's stock valued at $254,424,000 after acquiring an additional 1,610,130 shares during the last quarter. Parkman Healthcare Partners LLC acquired a new position in Viridian Therapeutics in the 3rd quarter valued at $9,669,000. Lord Abbett & CO. LLC purchased a new position in Viridian Therapeutics in the 3rd quarter valued at $8,917,000. Novo Holdings A S boosted its stake in Viridian Therapeutics by 19.3% during the 3rd quarter. Novo Holdings A S now owns 2,385,000 shares of the company's stock worth $54,259,000 after purchasing an additional 385,000 shares during the last quarter. Finally, JPMorgan Chase & Co. boosted its stake in Viridian Therapeutics by 218.5% during the 3rd quarter. JPMorgan Chase & Co. now owns 400,351 shares of the company's stock worth $9,108,000 after purchasing an additional 274,641 shares during the last quarter.

Viridian Therapeutics Stock Up 3.3 %

NASDAQ:VRDN traded up $0.65 during trading hours on Thursday, hitting $20.08. The stock had a trading volume of 1,462,045 shares, compared to its average volume of 1,266,108. The company has a market cap of $1.59 billion, a PE ratio of -4.66 and a beta of 1.13. The business has a 50 day simple moving average of $19.42 and a two-hundred day simple moving average of $19.40. Viridian Therapeutics, Inc. has a 1-year low of $11.40 and a 1-year high of $27.20. The company has a current ratio of 18.55, a quick ratio of 18.55 and a debt-to-equity ratio of 0.04.

Viridian Therapeutics (NASDAQ:VRDN - Get Free Report) last announced its quarterly earnings data on Tuesday, November 12th. The company reported ($1.15) earnings per share for the quarter, missing the consensus estimate of ($1.11) by ($0.04). The company had revenue of $0.09 million for the quarter, compared to analyst estimates of $0.08 million. Viridian Therapeutics had a negative return on equity of 70.12% and a negative net margin of 85,127.16%. Analysts predict that Viridian Therapeutics, Inc. will post -4.03 EPS for the current year.

Analysts Set New Price Targets

VRDN has been the topic of several research reports. Royal Bank of Canada raised their price target on shares of Viridian Therapeutics from $44.00 to $47.00 and gave the stock an "outperform" rating in a research note on Tuesday, December 17th. TD Cowen began coverage on Viridian Therapeutics in a research report on Monday, November 25th. They issued a "buy" rating for the company. HC Wainwright reaffirmed a "buy" rating and issued a $34.00 target price on shares of Viridian Therapeutics in a research note on Monday, December 16th. Wells Fargo & Company reissued an "equal weight" rating and issued a $27.00 price objective (down previously from $37.00) on shares of Viridian Therapeutics in a report on Thursday, December 19th. Finally, Needham & Company LLC reiterated a "buy" rating and issued a $38.00 target price on shares of Viridian Therapeutics in a report on Tuesday, January 7th. Three analysts have rated the stock with a hold rating and nine have issued a buy rating to the stock. According to data from MarketBeat.com, Viridian Therapeutics currently has a consensus rating of "Moderate Buy" and an average target price of $35.70.

Viridian Therapeutics Profile

Viridian Therapeutics, Inc, a biotechnology company, discover and develops treatments for serious and rare diseases. The company's product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R humanized monoclonal antibodies targeting IGF-1R and incorporating half-life extension technology for the treatment of TED.